AIM ImmunoTech (AIM) Operating Expenses (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Operating Expenses came in at $2.2 million in Q1 2026, down 38.16% YoY from $3.6 million in Q1 2025, and down 24.39% on a QoQ basis from $3.0 million in Q4 2025.
AIM ImmunoTech (AIM) Operating Expenses (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Operating Expenses data on file, last reported at $2.2 million in Q1 2026.
- Quarterly Operating Expenses fell 38.16% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.4 million (down 41.78% YoY) and the FY2025 annual result came in at $11.8 million, down 41.07% from the prior year.
- Operating Expenses declined to $2.2 million in Q1 2026, from $3.0 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $14.1 million in Q4 2023 to a low of $2.2 million in Q1 2026.
- A 5-year average of $5.1 million and a median of $4.5 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses jumped 150.69% — and 2024, when it plunged 58.06%.
- Tracing AIM's Operating Expenses over 5 years: stood at $5.6 million in 2022, then jumped by 150.69% to $14.1 million in 2023, then plunged by 58.06% to $5.9 million in 2024, then tumbled by 49.61% to $3.0 million in 2025, then retreated by 24.39% to $2.2 million in 2026.
- The last three Operating Expenses figures came in at $2.2 million (Q1 2026), $3.0 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | 3.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.54 Mn |
| Mar 31, 2026 | 2.25 Mn |
| Dec 31, 2025 | 2.97 Mn |
| Sep 30, 2025 | 2.47 Mn |
| Jun 30, 2025 | 2.67 Mn |
| Mar 31, 2025 | 3.64 Mn |
| Dec 31, 2024 | 5.90 Mn |
| Sep 30, 2024 | 4.52 Mn |
| Jun 30, 2024 | 3.74 Mn |
| Mar 31, 2024 | 5.77 Mn |
| Dec 31, 2023 | 14.07 Mn |
| Sep 30, 2023 | 8.20 Mn |
| Jun 30, 2023 | 5.50 Mn |
| Mar 31, 2023 | 4.34 Mn |
| Dec 31, 2022 | 5.61 Mn |
| Sep 30, 2022 | 6.54 Mn |
| Jun 30, 2022 | 4.73 Mn |
| Mar 31, 2022 | 3.19 Mn |
| Dec 31, 2021 | 7.50 Mn |
| Sep 30, 2021 | 3.96 Mn |